Pharsight

Temodar patents expiration

TEMODAR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623868 MERCK SHARP DOHME Processes of making and using pharmaceutical formulations of antineoplastic agents
Feb, 2023

(7 months ago)

US7786118 MERCK SHARP DOHME Pharmaceutical formulations of antineoplastic agents
Feb, 2023

(7 months ago)

US6987108 MERCK SHARP DOHME Pharmaceutical formulations of antineoplastic agents and processes of making and using the same
Sep, 2023

(16 days ago)

Temodar is owned by Merck Sharp Dohme.

Temodar contains Temozolomide.

Temodar has a total of 3 drug patents out of which 3 drug patents have expired.

Expired drug patents of Temodar are:

  • US8623868
  • US7786118
  • US6987108

Temodar was authorised for market use on 27 February, 2009.

Temodar is available in powder;intravenous dosage forms.

The generics of Temodar are possible to be released after 08 September, 2023.

Drugs and Companies using TEMOZOLOMIDE ingredient

Market Authorisation Date: 27 February, 2009

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

TEMODAR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic